Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Results Enrollment began in early 2018 and is anticipated to end in the Fall of 2021 with study completion in 2023. Currently, all results remain blinded. As of May 2021, a total of 222 participants ...

Background Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are challenging ...

Objective This systematic review seeks to survey existing literature concerning systemic lupus erythematosus (SLE)-related thrombosis risk mechanisms within six pro-coagulable categories: ...

Background Single-cell RNA-sequencing (scRNA-seq) has been recently applied in systemic lupus erythematosus (SLE) to define distinct cellular composition and transcriptional signatures, greatly ...

Results 293 visits from 124 patients were included, 116 (93.5%) were women with a mean age at diagnosis of 35.2 (12.6) years. Mean CQR at baseline was 75.9 (13.6) and at the end of follow-up was 76.4 ...

Background Proliferative lupus nephritis (LN) is characterized by robust glomerular and tubulo- interstitial inflammation, sub-endothelial deposits of immunoglobulin, and increased endothelial cell ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.

Objective The heterogeneity of lupus clinical manifestations makes it difficult to precisely characterize the full spectrum of patient profiles with traditional real-life (claims) data sources. This ...

Background People with SLE (and their doctors) are concerned about the risk of COVID-19 infection, yet some patients still harbor concerns regarding vaccination. The first mRNA SARS-CoV-2 vaccines ...

Background Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms driving UV- ...

Results When comparing OT images of a total of 48 PIPs from healthy volunteers and 160 PIPs from SLE patients, an AUC of 0.79 is obtained (figure 3) with corresponding sensitivity and specificity of ...